James Kihara Acadia Pharmaceuticals Inc (ACAD) insider trading activity

James Kihara is PRINCIPAL ACCOUNTING OFFICER of ACADIA PHARMACEUTICALS INC. Currently has a direct ownership of 14,370 shares of ACAD, which is worth approximately $222,447. The most recent transaction as insider was on May 02, 2024, when has been sold 1,326 shares (Common Stock) at a price of $16.94 per share, resulting in proceeds of $22,462. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 14.4K

0% 3M change

33.33% 12M change

Total Value Held $222,447

James Kihara Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
May 02 2024	SELL Open market or private sale	$22,462 $16.94 p/Share	1,326 Reduced 8.45%	14,370 Common Stock
May 01 2024	BUY Exercise of conversion of derivative security	-	2,596 Added 14.19%	15,696 Common Stock
Apr 08 2024	SELL Open market or private sale	$31,987 $17.87 p/Share	1,790 Reduced 12.02%	13,100 Common Stock
Apr 07 2024	BUY Exercise of conversion of derivative security	-	1,489 Added 9.09%	14,890 Common Stock
Apr 05 2024	BUY Exercise of conversion of derivative security	-	2,010 Added 13.04%	13,401 Common Stock
Feb 26 2024	SELL Open market or private sale	$11,693 $24.67 p/Share	474 Reduced 3.99%	11,391 Common Stock
Feb 23 2024	BUY Exercise of conversion of derivative security	-	840 Added 6.61%	11,865 Common Stock
Dec 15 2023	SELL Open market or private sale	$56,600 $28.3 p/Share	2,000 Reduced 15.36%	11,025 Common Stock
Nov 20 2023	SELL Open market or private sale	$44,940 $22.64 p/Share	1,985 Reduced 13.22%	13,025 Common Stock
Nov 17 2023	BUY Exercise of conversion of derivative security	-	3,964 Added 20.89%	15,010 Common Stock
Sep 15 2023	SELL Open market or private sale	$51,760 $25.88 p/Share	2,000 Reduced 15.65%	10,778 Common Stock
Jun 15 2023	SELL Open market or private sale	$48,300 $24.15 p/Share	2,000 Reduced 17.95%	9,144 Common Stock
May 17 2023	SELL Open market or private sale	$133,807 $22.5 p/Share	5,947 Reduced 34.8%	11,144 Common Stock
May 17 2023	BUY Exercise of conversion of derivative security	-	11,894 Added 41.04%	17,091 Common Stock
Apr 10 2023	SELL Open market or private sale	$9,487 $18.14 p/Share	523 Reduced 9.14%	5,197 Common Stock
Apr 07 2023	BUY Exercise of conversion of derivative security	-	1,489 Added 20.65%	5,720 Common Stock
Apr 06 2023	SELL Open market or private sale	$12,730 $18.16 p/Share	701 Reduced 14.21%	4,231 Common Stock
Apr 05 2023	BUY Exercise of conversion of derivative security	-	2,009 Added 28.94%	4,932 Common Stock
Feb 24 2023	SELL Open market or private sale	$6,573 $18.78 p/Share	350 Reduced 10.69%	2,923 Common Stock
Feb 23 2023	BUY Exercise of conversion of derivative security	-	840 Added 20.42%	3,273 Common Stock
Apr 08 2022	SELL Open market or private sale	$27,726 $27.05 p/Share	1,025 Reduced 29.64%	2,433 Common Stock
Apr 07 2022	BUY Exercise of conversion of derivative security	-	2,977 Added 46.26%	3,458 Common Stock
Feb 23 2022	SELL Open market or private sale	$8,544 $23.8 p/Share	359 Reduced 42.74%	481 Common Stock
Feb 23 2022	BUY Exercise of conversion of derivative security	-	840 Added 50.0%	840 Common Stock

James Kihara

PRINCIPAL ACCOUNTING OFFICER

San Diego, CA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells ACAD shares.

Notify only if

Value

Insider Trading

Get notified when an Acadia Pharmaceuticals Inc insider buys or sells ACAD shares.

Notify only if

Operation

Value

Type

News

Receive news related to ACADIA PHARMACEUTICALS INC

Track Activities on ACAD

Account